SHANGHAI, June 8, 2026 — OriCell Therapeutics Holdings Limited ( The “Company” or “Oricell”) , today announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confirmatory Phase II clinical trial in patients with GPC3-positive advanced hepatocellular carcinoma (HCC). The study is designed as a prospective, randomised, open-label, multi-centre registration trial evaluating the efficacy and safety of Ori-C101 in patients who have failed two or more prior lines of therapy.
SHANGHAI, China, June 1, 2026 —— Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory hepatocellular carcinoma (HCC). The data, selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight a potential new benchmark for patients who have exhausted standard therapies.
Shanghai, China – May 22, 2026 – Oricell Therapeutics Co., Ltd. (“Oricell” or the “Company”), a clinical-stage biotechnology company dedicated to developing innovative cell therapies, today announced that positive Phase Ib clinical data from its proprietary autologous CAR-T therapy, Ori-C101, targeting GPC3-positive advanced hepatocellular carcinoma (HCC) have been selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data will be presented by Prof. Jian Zhou, Director of Zhongshan Hospital affiliated to Fudan University, on behalf of the investigators.
Deep Dive with Oricell's Co-founder, Dr. Helen Yang: From Vision to Industry Milestones https://pharmaboardroom.com/interviews/helen-yang-co-founder-chairwoman-ceo-oricell-therapeutics/
SHANGHAI, China, April 10, 2026 – Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.
SHANGHAI, China, January 12, 2026 – Oricell Therapeutics Holdings Limited (“Oricell” or “the Company”), a global leader in innovative cancer immunotherapy, announced today the closing of a $70M Series C1 financing.
Shanghai, China, September 10, 2025 -- Oricell Therapeutics ("Oricell"), a clinical-stage biotech company at the forefront of oncology immunotherapy and advanced cell therapy development, today announced that Dr. Peter He, Oricell's co-founder and chief scientific officer, presented Oricell's proprietary technology platform, pipeline progress, global footprint, and strategic vision at the Morgan Stanley 23rd Annual Global Healthcare Conference taking place on September 8th-10th in New York City.
On August 21, 2025, the inaugural Evercore China Biotech Summit—hosted by leading global investment bank Evercore—wrapped up successfully in Shanghai, China. Oricell Therapeutics, a pioneer in China’s cell therapy sector, was the sole cell therapy firm invited to deliver a keynote at the summit. Dr. Peter He, Oricell’s co-founder and chief scientific officer, not only delivered an insightful presentation on the company’s cutting-edge technology platforms and pipeline advancements but also engaged in in-depth discussions with leading global specialists.
Shanghai, China & New Jersey, USA (December 6th, 2024) — Oricell Therapeutics (Oricell), a clinical-stage biotech company aiming to lead in oncology immunotherapy innovation and focusing on developing advanced cell therapies, today announced that it will present a poster on its novel multi-specific CAR-T therapy targeting BCMA, GPRC5D, and CD38 in heterogeneous multiple myeloma (MM) at the 2024 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA from December 7-10, 2024. This innovative therapy aims to address the challenges posed by antigen heterogeneity and the suppressive tumor microenvironment in extramedullary disease, ultimately improving clinical outcomes and durability for patients with relapsed/refractory (R/R) MM.
沪公网安备 31011502019994号